Guess which All Ords ASX healthcare stock just surged 11% on FDA news

Investors are sending the ASX healthcare stock soaring on Monday.

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) is up 0.4% in late morning trade on Monday, with one ASX healthcare stock doing plenty of the heavy lifting.

The high-flying company in question is Silicon Valley-based EBR Systems Inc (ASX: EBR), which is focused on treating cardiac rhythm disease.

EBR Systems shares closed on Friday trading at $1.365. At the time of writing, they are 7.8% higher at $1.47 after leaping to an intraday high of $1.52, up 11.4%.

As you can see on the chart below, that sees the ASX healthcare stock up a very, well, healthy 138% over the past 12 months.

Created with Highcharts 11.4.3Ebr Systems PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Here's what's spurring investor interest today.

ASX healthcare stock leaps on FDA update

Investors are bidding up the EBR Systems share price after the company, developing the world's only wireless cardiac pacing device for heart failure (WiSE System), announced that the US Food and Drug Administration (FDA) has scheduled the manufacturing Pre-Approval Inspection (PAI) to commence next week, on 14 January.

The ASX healthcare stock had previously anticipated that the PAI would start this week. However, management noted that the one-week delay won't impact the expected FDA regulatory approval timing, which was said to remain on track for the first quarter of calendar year 2025.

Commercial launch is then projected to take place later this year.

According to the release, the PAI's purpose is to confirm that EBR's manufacturing procedures comply with US quality system regulations and ensure that EBR can consistently produce devices that meet these approved specifications.

EBR reiterated that the FDA has previously said that the onsite Biomedical Monitoring (BIMO) audit is unlikely to be a requirement prior to final approval.

The Breakthrough Device designation for the WiSE System enables EBR to receive prioritised review and interactive communication with the FDA until the review process is completed.

The ASX healthcare stock initially released details of the FDA's review process on 30 September.

At the time, EBR Systems CEO John McCutcheon said:

We are delighted that our PMA application has progressed to substantive review by the FDA, effectively moving into the final stages of our regulatory timeline. The FDA moved quickly through this step, which could have taken up to 45 days.

This significant milestone brings us even closer to US commercialisation and to making available our life-changing WiSE technology to heart failure patients in need.

That announcement came shortly after the ASX healthcare stock secured $50 million in new funding. The company noted this provided it with a "cash runway" to get it through the FDA approval process, adding that the funds would also support it through early commercialisation and revenue growth.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Healthcare Shares

These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Up 250% in a year, how much higher can this ASX healthcare share climb?  

The future looks promising for this biotech firm after delivering a record-quarterly result.

Read more »